Skip to main content
. 2022 Aug 1;20:4402–4414. doi: 10.1016/j.csbj.2022.07.030

Fig. 8.

Fig. 8

The immunotherapy response and potential drugs between high-risk and low-risk groups in TCGA-LIHC. (A-D) IPS score between two groups. (E) The potential drugs for HCC treatment. (F) The 2D structure of HLI-373. (G) The 3D structure of HLI-373. Ns: not significant, P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001.